{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047564","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.543272+00:00","generated_at":"2026-05-21T15:14:59.458689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics Q1 net loss $15.4M; workforce cut ~50%; sirexatamab shows positive Phase 2 data","bullets":["Net loss of $15.4M in Q1 2025 vs $13.8M in Q1 2024; R&D expense rose to $12.9M.","Cash and equivalents $32.7M at March 31, 2025.","Positive DeFianCe study data: 32% higher ORR and 3.5-month PFS benefit in DKK1-high CRC patients.","Strategic restructuring reduced workforce by ~50% to prioritize sirexatamab and FL-501.","Engaged financial advisor to explore business development for sirexatamab registrational Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047564","json":"https://secwatch.observer/filing/0001104659-25-047564.json","markdown":"https://secwatch.observer/filing/0001104659-25-047564.md","text":"https://secwatch.observer/filing/0001104659-25-047564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925047564/0001104659-25-047564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925047564/tm2514827d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:14:59.458689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}